ClinicalTrials.gg
RecruitingNCT07571343Updated Oct 26, 2026

Fueling Labor: Protein Supplementation for Intrapartum Glucose Control

An interventional study of High-Protein Beverage (Genius Gourmet Sparkling Protein Water) and Standard Clear Liquid Diet in Diabetes During Pregnancy, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Medical College of Wisconsin · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 26, 2026Now RecruitingSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 251 studies in Diabetes, Gestational with a site in United States — 52 open to participants now, 65 under way, 2 of them phase 3. Diabetes, Gestational · United States.

Planned enrollment
110th of 194
60 · median 80
Started
2026
with 9 others
No phase
154 of 251
31 open now
Primary completion
2028-07
later than 53 of 64 live
Registered
245th of 251
by date

Among the 251 studies in Diabetes, Gestational with a site in United States, this one is the 110th largest by planned enrollment of the 194 interventional ones that give a count, is one of 10 that started in 2026, is one of 154 with no phase, reaches primary completion later than 53 of the 64 other live ones, and was the 245th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

52 of the 251 studies in Diabetes, Gestational with a site in United States are open now. Recruiting first, the newest first:

46 more — sign in →

All 52 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 251 studies in Diabetes, Gestational with a site in United States, or all of them as a file.
02

Study summary

The goal of this study is to learn if high-protein drinks during labor can improve blood sugar control in pregnant women with insulin-treated diabetes. It will also help us learn if this approach is acceptable and well-tolerated by patients. The main questions it aims to answer are:

  • Does drinking high-protein beverages during labor keep blood sugar in a healthier range compared to drinking standard clear liquids?
  • How do participants feel about drinking protein beverages during labor, and does it affect their energy levels and birth experience?
  • Is the baby less likely to have low blood sugar after birth when the mother drinks protein beverages during labor?

Researchers will compare women who drink high-protein beverages to women who drink standard clear liquids (like juice, broth, and popsicles) to see if protein drinks help keep blood sugar more stable during labor.

Participants will:

  • Wear a small, painless glucose sensor on their arm from when labor starts until about one week after giving birth
  • Be randomly assigned to either drink a clear protein beverage every 4 hours during labor OR drink standard clear liquids as usual
  • Complete short surveys about how tired they feel during labor, their overall birth experience, and their overall experience with the glucose sensor
Read the detailed description

Background and Rationale:

Optimal nutrition during labor for patients with insulin-treated diabetes in pregnancy remains poorly defined. While current guidelines support clear liquid intake during labor, the metabolic effects of different nutritional strategies-particularly high-protein supplementation-have not been studied. Maintaining stable maternal glucose levels during labor is essential to reducing neonatal complications, including hypoglycemia. However, standard clear liquids may cause glucose excursions, while prolonged fasting may contribute to maternal fatigue and metabolic stress.

Continuous glucose monitoring (CGM) technology provides real-time assessment of glucose patterns during labor, offering a novel opportunity to evaluate how targeted nutritional interventions influence maternal glycemic stability. Recent evidence suggests that maternal time above glucose target range during labor is associated with neonatal hypoglycemia, yet no studies have examined whether protein-based oral supplementation can improve intrapartum glucose control compared to standard clear liquids.

Study Objectives:

This pilot randomized controlled trial evaluates the feasibility and metabolic impact of high-protein oral supplementation during labor in patients with insulin-treated gestational or type 2 diabetes undergoing induction of labor. The study aims to:

  1. Assess feasibility and acceptability of implementing a CGM-guided intrapartum nutritional protocol
  2. Compare CGM-derived glycemic metrics (including percent time above range >110 mg/dL, time in range, and glycemic excursions) between high-protein supplementation and standard clear liquids
  3. Explore associations with maternal experience (fatigue, birth satisfaction) and neonatal outcomes

Study Design:

Sixty participants with insulin-treated gestational diabetes (GDM A2) or type 2 diabetes will be randomized 1:1 to receive either high-protein nutritional supplements (30g protein, 0g carbohydrate) every 4 hours during labor or standard institutional clear liquid diet. All participants will wear a blinded CGM (Abbott Freestyle Libre) from admission through delivery and for up to 7 days postpartum. The primary outcome is percent time above glucose range (>110 mg/dL) during labor. Secondary outcomes include other CGM metrics, maternal fatigue and satisfaction scores, labor outcomes, and neonatal hypoglycemia.

Significance:

This pilot study will generate critical preliminary data on the metabolic effects, patient-centered outcomes, and feasibility of high-protein intrapartum supplementation, informing the design of future larger trials to optimize evidence-based nutritional management during labor for patients with insulin-treated diabetes.

03

Conditions studied

  • Diabetes During Pregnancy

Browse trials for

Keywords

  • Intrapartum glucose control
  • continuous glucose monitoring
  • Protein supplementation
  • diabetes in pregnancy
  • time above range
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • Singleton pregnancy
  • Gestational age ≥37 0/7 weeks at time of induction
  • Diagnosis of gestational diabetes requiring insulin therapy (GDM A2) or pre-existing Type 2 diabetes managed with insulin during pregnancy
  • Admission to labor and delivery for induction of labor
  • Able and willing to provide

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes mellitus
  • Multifetal gestation
  • Major fetal anomalies or conditions affecting neonatal glucose regulation
  • Stillbirth
  • Planned cesarean delivery
  • Inability to provide consent
  • to oral intake (e.g., NPO status for clinical indication)
  • Known allergy or intolerance to study materials, including components of the high-protein supplement or CGM device
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    High-Protein Supplementation

    Participants will be offered Genius Gourmet Sparkling Protein Water (approximately 30 g protein, 0 g carbohydrate, 0 g fat, 130 kcal per 12-ounce serving) every 4 hours beginning at randomization until delivery. Consumption is voluntary. All participants will wear a blinded CGM from admission through 7 days postpartum.

    Dietary Supplement: High-Protein Beverage (Genius Gourmet Sparkling Protein Water) · Device: Continuous Glucose Monitoring (Abbott Freestyle Libre)

  • Active comparator
    Standard Clear Liquid Diet

    Participants will receive standard institutional clear liquid diet (water, ice chips, clear fruit juices, clear carbonated beverages, popsicles, clear broth, gelatin) ad libitum throughout labor per routine institutional practice. All participants will wear a blinded CGM from admission through 7 days postpartum.

    Other: Standard Clear Liquid Diet · Device: Continuous Glucose Monitoring (Abbott Freestyle Libre)

Interventions

  • Dietary supplementHigh-Protein Beverage (Genius Gourmet Sparkling Protein Water)

    Clear, carbonated, commercially available high-protein nutritional supplement containing approximately 30 g protein, 0 g carbohydrate, 0 g fat, and 130 kcal per 12-ounce serving. Offered every 4 hours during labor. Multiple flavors available (participant's choice).

  • OtherStandard Clear Liquid Diet

    Standard institutional clear liquid diet including water, ice chips, clear fruit juices (e.g., apple juice), clear carbonated beverages (e.g., ginger ale), popsicles, clear broth, and gelatin. Carbohydrate-containing clear liquids permitted per standard practice.

  • DeviceContinuous Glucose Monitoring (Abbott Freestyle Libre)

    Abbott Freestyle Libre 2 or Libre 3 CGM sensor placed on upper arm upon admission. Sensor remains in place through delivery and up to 7 days postpartum. CGM data blinded to participants and clinical staff during labor.

06

What researchers measure

Primary outcomes

  1. Percent Time Above Range (TAR >110 mg/dL) During Labor

    Percentage of CGM readings exceeding 110 mg/dL during labor, calculated as the proportion of valid CGM readings \>110 mg/dL divided by total valid readings, expressed as a percentage.

    Time frame: From admission to delivery (expected ≤72 hours)

Secondary outcomes

  1. Time in Range

    Percentage of CGM readings within target range during labor (70-110 mg/dL)

    Time frame: From admission to delivery (expected ≤72 hours)

  2. Glycemic Variability

    Standard deviation and coefficient of variation of CGM glucose values during labor.

    Time frame: From admission to delivery (expected ≤72 hours)

  3. Hyperglycemic Excursions

    Number of episodes of CGM glucose \>140 mg/dL, separated by ≥15 minutes below threshold.

    Time frame: From admission to delivery (expected ≤72 hours)

  4. Hypoglycemic Events

    Number of CGM glucose values \<70 mg/dL during labor.

    Time frame: From admission to delivery (expected ≤72 hours)

  5. Total Insulin Use During Labor

    Total insulin administered (units)

    Time frame: From admission to delivery (expected ≤72 hours)

  6. Maternal Fatigue Score (VAS)

    Visual Analog Scale for fatigue (0-10), where higher scores indicate greater fatigue.

    Time frame: Admission and every 4 hours until delivery (expected ≤72 hours)

  7. Labor Agentry Scale Score (LAS)

    Labor Agentry Scale (LAS), a 29-item validated measure of perceived control during labor. Each item is scored on a 7-point Likert scale. Total scores range from 29 to 203, with higher scores indicating greater perceived control.

    Time frame: 24-48 hours postpartum

  8. Birth Satisfaction Scale-Revised Score

    A 10-item validated measure of overall birth satisfaction. Each item is scored on a 0-4 scale. Total scores range from 0 to 40, with higher scores indicating greater birth satisfaction.

    Time frame: 24-48 hours postpartum

  9. Maternal Emesis

    Number of vomiting episodes during labor documented by clinical record or participant report.

    Time frame: From admission to delivery (expected ≤72 hours)

  10. Mode of Delivery

    Mode of delivery categorized as spontaneous vaginal, operative vaginal, or cesarean delivery.

    Time frame: At delivery

  11. Neonatal Hypoglycemia

    Blood glucose \<40 mg/dL.

    Time frame: First 24 hours of life

  12. Neonatal Intensive Care Unit (NICU) Admission

    Admission to neonatal intensive care unit (yes/no).

    Time frame: From birth through hospital discharge (expected ≤28 days)

  13. Neonatal Glucose Supplementation

    Requirement for oral or IV glucose.

    Time frame: First 24 hours of life

  14. Postpartum Time in Range

    Percentage of CGM readings within postpartum target range (70-140 mg/dL).

    Time frame: Delivery to 7 days postpartum

  15. Composite Maternal Morbidity

    Composite maternal morbidity defined as occurrence of any of the following conditions: postpartum hemorrhage requiring intervention such as estimated blood loss \>1000 milliliters (mL) or uterotonics, tranexamic acid, blood transfusion or surgical interventions (dilation and curettage, Bakri, Jada, laparotomy, interventional radiology), endometritis, intraamniotic infection, obstetric anal sphincter injury (OASIS), ICU admission, amniotic fluid embolism, and death.

    Time frame: Up to 6 weeks postpartum

  16. Umbilical Cord Blood Gas Values

    Umbilical arterial cord blood gas values (pH, partial pressure of carbon dioxide (pCO₂), and base excess)

    Time frame: At delivery

  17. Infant Healthcare Utilization

    Healthcare utilization including hospitalizations, emergency department visits, urgent care visits, and primary care visits assessed via medical record and parental report.

    Time frame: Birth to 1 year of life

  18. Labor Duration

    Duration of first, second, and third stages of labor measured in hours

    Time frame: From admission to delivery (expected ≤72 hours)

  19. Infant Weight

    Infant weight in kilograms

    Time frame: Birth to 1 year of life

  20. Infant Length

    Infant length in centimeters

    Time frame: Birth to 1 year of life

  21. NICU Length of Stay

    Duration of NICU hospitalization measured in days.

    Time frame: From birth through hospital discharge (expected ≤28 days)

  22. Respiratory Support

    Requirement for respiratory support including supplemental oxygen, continuous positive airway pressure (CPAP), or mechanical ventilation (intubation).

    Time frame: From birth through hospital discharge (expected ≤28 days)

  23. Neonatal Jaundice Requiring Phototherapy

    Need for phototherapy for neonatal hyperbilirubinemia.

    Time frame: From birth through hospital discharge (expected ≤28 days)

  24. Neonatal Hypoglycemia Treatment

    Requirement for glucose supplementation (oral or intravenous).

    Time frame: From birth through hospital discharge (expected ≤28 days)

  25. Neonatal Sepsis

    Documented clinical suspicion or laboratory-confirmed neonatal sepsis.

    Time frame: From birth through hospital discharge (expected ≤28 days)

  26. Perinatal Death

    Fetal or neonatal death occurring from birth through hospital discharge.

    Time frame: From birth through hospital discharge (expected ≤28 days)

  27. Neonatal Resuscitation Level

    Level of resuscitation at birth categorized as none, stimulation only, positive pressure ventilation, or advanced resuscitation.

    Time frame: At delivery

Other outcomes

  1. Recruitment Rate

    Proportion of eligible patients who consent to participation.

    Time frame: Recruitment period (up to 18 months)

  2. Intervention Adherence

    Proportion of scheduled supplements consumed (measured as proportion of scheduled doses consumed)

    Time frame: From admission to delivery (expected ≤72 hours)

  3. CGM Data Completeness

    Proportion of the intrapartum period with valid CGM data

    Time frame: From admission to delivery (expected ≤72 hours)

  4. Survey Completion Rate

    Proportion of participants completing postpartum surveys (LAS and BSS-R).

    Time frame: 48 hours postpartum

  5. Number of Maternal Healthcare Encounters

    Number of healthcare encounters including hospitalizations, emergency department visits, urgent care visits, and primary care visits.

    Time frame: From hospital discharge to 6 weeks postpartum

  6. Developmental screening

    Development assessed using Ages and Stages Questionnaire, Third Edition (ASQ-3), a parent-completed developmental screening tool with five domains (communication, gross motor, fine motor, problem-solving, personal-social). Domain scores range from 0 to 60, with lower scores indicating greater developmental concern. This is a screening tool; scores are interpreted relative to age-specific cutoffs.

    Time frame: First year of life

  7. Randomization Success

    Proportion of consented patients successfully randomized

    Time frame: Recruitment period (up to 18 months)

  8. Protocol Deviations

    Number and type of deviations from the study protocol.

    Time frame: Recruitment period (up to 18 months)

  9. Retention

    Proportion of randomized participants with complete primary outcome data

    Time frame: From randomization through delivery hospitalization(expected ≤7 days)

  10. Postpartum CGM Tolerability

    Structured questionnaire assessing irritation, comfort, interference, and willingness to reuse CGM using structured Likert-style responses (e.g., none/mild/moderate/severe for irritation; yes/no for willingness to use CGM again). No composite score is generated.

    Time frame: Within 7 days postpartum

  11. Postpartum CGM Wear Time

    Total postpartum CGM wear time (hours).

    Time frame: Delivery to 7 days postpartum

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jul 2028, 24 months after the start.

Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 24 months is below that.

Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
May 6, 2026
StartActual
Jul 1, 2026
Primary completionEst.
Jul 30, 2028
CompletionEst.
Jul 30, 2028
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 26, 2026
Sites
Froedtert Hospital is now Recruiting
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Not yet recruiting→Recruiting
    Froedtert Hospital is now Recruiting
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07571343
Responsible party
Brock E. Polnaszek, MD MPH (Assistant Professor & Clinical Investigator, Medical College of Wisconsin) — Principal investigator
First posted
May 6, 2026
Start date
Jul 1, 2026
Primary completion
Jul 30, 2028 (estimated)
Completion
Jul 30, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

Sukanya Skandarajah
Contact
sskandarajah@mcw.edu
4148055337
Brock Polnaszek, MD
Contact
bpolnaszek@mcw.edu
4148056624

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion